Intravenous psilocybin attenuates mechanical hypersensitivity in a rat model of chronic pain

A single intravenous dose of psilocybin reduces mechanical hypersensitivity for 28 days in a rat model of formalin-induced chronic pain, suggesting potential for treating chronic pain conditions. The study addresses a gap in research on psilocybin's effectiveness for chronic pain, as prior work focused on psychiatric disorders and substance abuse. No systematic investigation had previously examined psilocybin's impact on chronic pain indices.

Study at a glance

Abstract

There is a renewed interest in psychedelic drugs as potential therapeutic agents for the treatment of psychiatric disorders. In particular, psilocybin has shown promise for the treatment of refractory depression1 and major depressive disorder2, and has also been explored as a treatment for tobacco and alcohol abuse3,4. However, despite suggestive evidence5,6, there has been no systematic study to investigate the effectiveness of psilocybin in attenuating indices of chronic pain. To address this gap, we investigated the effect of psilocybin on mechanical hypersensitivity and thermal hyperalgesia in a well-established rat model of formalin-induced, centralized chronic pain7,8 and demonstrate that a single intravenous bolus administration of psilocybin can attenuate mechanical hypersensitivity for 28 days.